AACR 2026 Day 1: ctDNA, ADCs & Precision Oncology…

Key Takeaways

ctDNA emerges as clinical MRD marker: Discovery Science Plenary highlighted circulating tumor DNA detection methods for predicting outcomes across solid tumors, with applications in colorectal, breast, and pediatric cancers.
Novel ADCs and targeted therapies advance: Early-stage trials presented QLS5132 (CLDN6-targeted ADC) in ovarian cancer with 50–55.6% ORR, SYS6010 (EGFR-targeted ADC) in nasopharyngeal carcinoma with 31.5% ORR, and next-generation KRAS inhibitors in NSCLC.
Precision oncology reshapes treatment paradigms: Biomarker-driven strategies and molecular profiling—including STAG2 mutations in Ewing sarcoma and genetic heterogeneity in pediatric leukemias—are redefining risk stratification and therapy selection.
Immunotherapy and bispecific antibodies gain traction: Perioperative nivolumab (CheckMate 77T) and zanidatamab (HER2 bispecific antibody) show potential to improve outcomes and reduce chemotherapy burden in early-stage disease.

AACR 2026 Annual Meeting: Day 1 Oncology Highlights

The American Association for Cancer Research (AACR) Annual Meeting 2026 opened on Saturday, April 18, in San Diego with a landmark Discovery Science Plenary Session focused on minimal residual disease (MRD) detection in solid tumors. The session underscored the clinical utility of circulating tumor DNA (ctDNA) as a precision biomarker, cancer cell plasticity mechanisms, drug resistance evolution, and emerging therapeutic strategies across colorectal cancer, triple-negative breast cancer (TNBC), Ewing sarcoma, and pediatric leukemias. Day 1 presentations set the stage for a week of clinical trial updates, novel drug disclosures, and emerging technology showcases that promise to reshape oncology treatment paradigms.

Session Highlights: Discovery Science and Precision Biomarkers

ctDNA as a Minimal Residual Disease Sensor

David Landau, MD, PhD, of Weill Cornell Medicine, presented innovative whole genome mutational integration methods designed to overcome input ceiling limitations in deep targeted sequencing. His approach enables detection of sparse ctDNA in solid tumors and improves outcome prediction accuracy. This methodology addresses a critical gap in current MRD monitoring, where traditional sequencing depth constraints limit sensitivity in patients with low tumor burden.

ctDNA Applications in Colorectal Cancer Trials

Jeanne Tie, MD, of Peter MacCallum Cancer Centre, discussed the expanding role of ctDNA for patient selection and as a potential trial endpoint in colorectal cancer. Dr. Tie emphasized the need for global validation of ctDNA reduction correlating with disease-free survival, positioning ctDNA as a bridge between early molecular response and long-term clinical benefit. This approach could accelerate trial timelines and improve patient stratification in future studies.

Triple-Negative Breast Cancer: Post-Neoadjuvant ctDNA Prognostication

Marija Balic, MD, of the University of Pittsburgh and NSABP Foundation, presented results from the NSABP B-59/GBG-96-GeparDouze sub-study in early-stage TNBC. The analysis revealed that post-neoadjuvant ctDNA presence was linked to residual invasive disease and a greater than 10-fold higher risk of distant recurrence. This finding positions ctDNA as a powerful prognostic tool for identifying high-risk patients who may benefit from intensified adjuvant strategies or closer surveillance protocols.

Ewing Sarcoma: Molecular Profiling and Risk Stratification

Katherine Janeway, MD, of Boston Children's Hospital, highlighted STAG2 mutations as outcome-associated targets identified through molecular profiling of a Children's Oncology Group (COG) cohort. Dr. Janeway proposed a biomarker-driven risk group framework and called for prospective validation of STAG2 status in future pediatric sarcoma trials. This molecular approach offers potential for more precise risk assessment and treatment personalization in Ewing sarcoma.

Pediatric Leukemias: Precision Therapies Beyond Risk-Adapted Chemotherapy

Sarah Tasian, MD, MSc, of Children's Hospital of Philadelphia, stressed the importance of precision therapies tailored to genetic heterogeneity in B-cell and T-cell acute lymphoblastic leukemia (ALL). Dr. Tasian emphasized that moving beyond traditional risk-adapted chemotherapy requires comprehensive molecular profiling and targeted intervention strategies to improve outcomes in pediatric ALL populations.

Clinical Trial Updates: Novel Therapeutics Across Cancer Types

Non-Small Cell Lung Cancer: Immunotherapy and KRAS-Targeted Advances

CheckMate 77T (nivolumab perioperative therapy): Tina Cascone, MD, PhD, of MD Anderson Cancer Center, presented biomarker analyses from the CheckMate 77T trial, which led to FDA approval of nivolumab (Opdivo, Bristol Myers Squibb) in 2024 for resectable NSCLC. Day 1 presentations focused on predictive biomarkers to improve outcome stratification in this patient population.

Elisrasib (KRAS^G12C inhibitor): Emerging data on elisrasib demonstrated 12-month overall survival (OS) rates of 71–72% in NSCLC patients harboring KRAS^G12C mutations, with 70% of patients showing positive ctDNA at baseline. This next-generation KRAS inhibitor represents a significant advance for patients with previously difficult-to-target mutations.

ARTEMIS-101 (risvutatug rezetecan + adebrelimab): A Phase I trial combining risvutatug rezetecan (HS-20093/GSK5764227), a B7H3-targeted antibody-drug conjugate (ADC), with adebrelimab (a B7H3-targeted monoclonal antibody) in advanced nonsquamous NSCLC without targetable mutations was presented, highlighting the emerging role of dual-mechanism approaches in immunologically cold tumors.

Breast Cancer: Bispecific Antibodies and Chemotherapy-Sparing Strategies

Zanidatamab (HER2 bispecific antibody): Funda Meric-Bernstam, MD, of MD Anderson Cancer Center, presented an investigator-initiated Phase II trial of zanidatamab (Jazz Pharmaceuticals) in early-stage HER2-positive breast cancer. The bispecific antibody, which simultaneously engages two distinct HER2 epitopes, showed potential to avoid chemotherapy in selected early-stage patients—a paradigm shift toward de-escalation strategies in HER2-driven disease.

Pancreatic Cancer: KRAS-Targeted Combination Therapy

Daraxonrasib + gemcitabine/nab-paclitaxel: A Phase I/II trial of daraxonrasib, a next-generation KRAS^G12C inhibitor, combined with standard first-line chemotherapy (gemcitabine and nab-paclitaxel) in metastatic pancreatic ductal adenocarcinoma achieved a confirmed objective response rate (cORR) of 58%. This combination approach demonstrates the potential of KRAS-targeted therapy to enhance chemotherapy efficacy in previously chemotherapy-refractory pancreatic cancer.

Ovarian Cancer: CLDN6-Targeted ADC with Favorable Safety Profile

QLS5132 (CLDN6-targeted ADC): A Phase I trial of QLS5132, a claudin-6 (CLDN6)-targeted ADC, in platinum-resistant ovarian cancer demonstrated an objective response rate (ORR) of 50% across all doses and 55.6% at the 4.8 mg/kg dose level. Disease control rate (DCR) reached 94.4% overall and 100% at doses ≥3.2 mg/kg. Notably, the drug showed activity even in patients with low or undetectable CLDN6 expression. The safety profile was favorable, with no reported interstitial lung disease (ILD), ocular toxicity, mucositis, or febrile neutropenia—addressing common ADC-related toxicities.

Nasopharyngeal Carcinoma: EGFR-Targeted ADC in Post-Immunotherapy Disease

SYS6010 (EGFR-targeted ADC): A Phase I trial of SYS6010, an EGFR-targeted ADC, in advanced nasopharyngeal carcinoma post-PD1/platinum therapy showed an ORR of 31.5% (54 evaluable patients, including 1 complete response at 4.2 mg/kg). Disease control rate was 87%, with median progression-free survival (mPFS) of 7.5 months. Notably, EGFR monoclonal antibody-naïve patients achieved higher response rates of 42.9–50% at doses of 4.2–4.8 mg/kg, independent of EGFR expression levels—suggesting potential for broader patient populations.

Advanced Solid Tumors: Immunomodulatory and Checkpoint Approaches

Denikitug (CCR8 antibody): Bruno Bockorny, MD, of Beth Israel Deaconess Medical Center, presented Phase I data on denikitug, a CCR8-targeting monoclonal antibody, in advanced solid tumors. Among 52 evaluable patients, the ORR was 8% and DCR was 46%. Responders had received a median of 6 prior treatment lines, while disease control patients had received a median of 2 lines. Common treatment-related adverse events (TRAEs) included pruritus and rash, with no Grade 4 or 5 toxicities reported.

IPH5201 (CD39 monoclonal antibody) + durvalumab + neoadjuvant platinum chemotherapy (MATISSE trial): A Phase II perioperative trial combining IPH5201, a CD39-targeting monoclonal antibody, with durvalumab (an anti-PD-L1 agent, Imfinzi, AstraZeneca) and neoadjuvant platinum-based chemotherapy in resectable NSCLC presented interim safety and efficacy data, with post-surgery outcomes under evaluation.

Emerging Technologies and Precision Oncology Innovations

Circulating Tumor DNA (ctDNA) Sequencing Platforms

The Discovery Science Plenary emphasized advances in ctDNA detection methodologies, particularly whole genome mutational integration approaches that overcome traditional sequencing depth limitations. These platforms enable real-time MRD monitoring and early detection of treatment resistance, positioning ctDNA as a foundational technology for precision oncology. Institutions including Weill Cornell Medicine and Peter MacCallum Cancer Centre are leading validation efforts to establish ctDNA reduction as a surrogate endpoint in clinical trials.

Molecular Profiling and Biomarker-Driven Risk Stratification

Day 1 presentations highlighted the expanding role of comprehensive molecular profiling in pediatric and adult malignancies. The Children's Oncology Group (COG) cohort analysis of STAG2 mutations in Ewing sarcoma exemplifies how genomic profiling can identify outcome-associated biomarkers and enable prospective risk stratification. Similarly, genetic heterogeneity mapping in pediatric ALL (B-cell and T-cell subtypes) is driving precision therapy selection beyond traditional chemotherapy-based risk adaptation.

Antibody-Drug Conjugate (ADC) Engineering and Payload Innovation

Multiple Day 1 presentations showcased next-generation ADC platforms with improved serum stability and reduced off-target toxicity. Preclinical data from CStone Pharmaceuticals on CS5007, an EGFR/HER3-targeted ADC, emphasized enhanced serum stability as a key advancement. Clinical trials of QLS5132 (CLDN6-targeted) and SYS6010 (EGFR-targeted) demonstrated favorable safety profiles with minimal ILD, ocular toxicity, and mucositis—addressing historical ADC limitations. These engineering advances expand the therapeutic window and enable broader patient populations to benefit from ADC-based therapies.

Bispecific and Trispecific Antibody Platforms

The zanidatamab Phase II trial in early-stage HER2-positive breast cancer exemplifies the clinical potential of bispecific antibodies that simultaneously engage multiple epitopes or targets. These engineered antibodies offer enhanced target engagement, improved effector function, and potential for reduced chemotherapy burden—representing a paradigm shift toward combination immunotherapy and targeted approaches.

First-in-Human and First-in-Class Investigational Agents

Day 1 sessions highlighted several first-in-human and first-in-class agents entering Phase I trials, including integrin inhibitors and genetically engineered tumor-infiltrating lymphocyte (TIL) therapies. These novel mechanisms of action address previously undruggable targets and expand the therapeutic arsenal for patients with limited treatment options.

Market and Investor Implications

Day 1 presentations underscore several key trends reshaping the oncology landscape:

ctDNA-driven trial design: Adoption of ctDNA as a surrogate endpoint could accelerate trial timelines and reduce development costs, benefiting biotech companies and contract research organizations (CROs) specializing in liquid biopsy technologies.
ADC market expansion: Favorable safety profiles and efficacy data for QLS5132, SYS6010, and other next-generation ADCs position this class as a major growth driver. Companies with differentiated ADC platforms (e.g., payload engineering, target selection) are well-positioned for commercial success.
KRAS inhibitor competition: Elisrasib and daraxonrasib data demonstrate the competitive landscape for KRAS^G12C and next-generation KRAS inhibitors. Multiple agents in development suggest market consolidation around efficacy, safety, and biomarker-driven patient selection.
De-escalation strategies: Zanidatamab and other chemotherapy-sparing approaches appeal to patients and payers seeking reduced toxicity and improved quality of life, creating market opportunities for agents enabling treatment de-escalation in early-stage disease.
Pediatric oncology precision medicine: Biomarker-driven approaches in Ewing sarcoma and pediatric ALL highlight growing investment in rare pediatric cancers, with potential for accelerated approval pathways and orphan drug designations.

What to Watch Next

As AACR 2026 continues through April 22, several key developments warrant close attention:

Sunday, April 19 clinical trial plenaries: Scheduled presentations will feature additional KRAS inhibitor data (elisrasib, zoldonrasib) in NSCLC, expanded ADC efficacy results, and immunotherapy combination trials.
New Drugs on the Horizon sessions: First-time public disclosures of 12 innovative agents spanning small molecules, biologics, bispecific/trispecific antibodies, macrocyclics, and bifunctional degraders will provide early insights into the next wave of oncology therapeutics.
ctDNA validation studies: Ongoing efforts to establish ctDNA reduction as a formal surrogate endpoint in regulatory submissions could reshape trial design across solid tumors and hematologic malignancies.
Pediatric oncology advances: Further presentations on STAG2-driven Ewing sarcoma risk stratification and precision ALL therapies will clarify the path to clinical implementation in pediatric populations.
ADC safety and efficacy updates: Extended follow-up data from QLS5132, SYS6010, and other ADC trials will inform optimal dosing, patient selection, and combination strategies.

Frequently Asked Questions

What is circulating tumor DNA (ctDNA) and why is it important in oncology?

Circulating tumor DNA (ctDNA) is fragmented DNA released by cancer cells into the bloodstream. It serves as a non-invasive biomarker for minimal residual disease (MRD) detection, treatment response monitoring, and early recurrence prediction. At AACR 2026, researchers presented advanced ctDNA sequencing methods using whole genome mutational integration to overcome detection limitations, enabling real-time MRD monitoring across solid tumors and hematologic malignancies. ctDNA is increasingly being evaluated as a surrogate endpoint in clinical trials to accelerate drug development and improve patient outcomes.

What are antibody-drug conjugates (ADCs) and how do they work?

Antibody-drug conjugates (ADCs) are engineered molecules combining a monoclonal antibody with a cytotoxic payload linked by a chemical linker. The antibody targets specific cancer cell surface antigens, delivering the toxic payload directly to tumor cells while minimizing exposure to healthy tissue. Day 1 presentations highlighted next-generation ADCs including QLS5132 (CLDN6-targeted) and SYS6010 (EGFR-targeted), which demonstrate improved serum stability and reduced off-target toxicities such as interstitial lung disease, ocular toxicity, and mucositis—addressing historical limitations of earlier ADC generations.

What are KRAS inhibitors and why are they significant for NSCLC and pancreatic cancer?

KRAS inhibitors are targeted therapies designed to block mutant KRAS proteins, which drive approximately 30% of human cancers. KRAS^G12C inhibitors (e.g., elisrasib, daraxonrasib) represent a breakthrough for patients with previously undruggable mutations. At AACR 2026, elisrasib demonstrated 12-month OS rates of 71–72% in NSCLC, while daraxonrasib combined with gemcitabine/nab-paclitaxel achieved 58% cORR in metastatic pancreatic cancer. These agents are reshaping treatment paradigms in NSCLC and pancreatic cancer, particularly in patients with limited prior options.

How are biomarkers like STAG2 mutations changing pediatric cancer treatment?

Biomarker-driven approaches enable precision medicine by identifying patient subgroups most likely to benefit from specific therapies. In Ewing sarcoma, STAG2 mutations identified through Children's Oncology Group (COG) molecular profiling are associated with distinct outcomes and may predict response to targeted interventions. Dr. Katherine Janeway proposed a biomarker-driven risk group framework to prospectively validate STAG2 status in future trials, allowing clinicians to tailor treatment intensity and select optimal therapies for individual patients based on molecular characteristics rather than clinical features alone.

What is the significance of zanidatamab in early-stage breast cancer?

Zanidatamab is a bispecific antibody that simultaneously engages two distinct HER2 epitopes, enhancing target engagement and effector function compared to conventional monoclonal antibodies. In the investigator-initiated Phase II trial presented by Dr. Funda Meric-Bernstam, zanidatamab showed potential to avoid chemotherapy in selected early-stage HER2-positive breast cancer patients. This represents a paradigm shift toward de-escalation strategies, reducing treatment toxicity and improving quality of life while maintaining or improving efficacy—a key goal in early-stage disease management.

Conclusion: Day 1 Sets the Stage for Precision Oncology Transformation

AACR 2026 Day 1 presentations underscore a fundamental shift in oncology toward precision medicine, biomarker-driven patient selection, and therapeutic de-escalation. The Discovery Science Plenary's emphasis on ctDNA as a clinical MRD sensor, combined with emerging data on next-generation ADCs, KRAS inhibitors, and bispecific antibodies, signals a new era in cancer treatment. Pediatric oncology advances in Ewing sarcoma and ALL demonstrate that molecular profiling is enabling risk stratification and precision therapy selection across age groups. As the meeting continues, clinicians, researchers, and industry stakeholders will closely monitor additional clinical trial updates, first-in-human drug disclosures, and technology innovations that promise to reshape oncology practice and improve patient outcomes. The convergence of liquid biopsy technologies, engineered antibodies, and targeted small molecules positions 2026 as a pivotal year for translating precision oncology from concept to clinical reality.

References

[1] AACR. "Live Updates from the AACR Annual Meeting 2026: Saturday, April 18." AACR Blog, April 18, 2026. https://www.aacr.org/blog/2026/04/18/live-updates-from-the-aacr-annual-meeting-2026-saturday-april-18/
[2] AACR Meeting News. "Second Clinical Trials Plenary Highlighted Results of Next-Generation Antibody-Drug Conjugates." AACR Meeting News. https://www.aacrmeetingnews.org/second-clinical-trials-plenary-highlighted-results-of-next-generation-antibody-drug-conjugates/
[3] AACR. "Live Updates from the AACR Annual Meeting 2026: Sunday, April 19." AACR Blog, April 19, 2026. https://www.aacr.org/blog/2026/04/19/live-updates-from-the-aacr-annual-meeting-2026-sunday-april-19/
[4] MD Anderson Cancer Center. "AACR Clinical Trial Feature: Advances Across Cancer Care." MD Anderson Newsroom. https://www.mdanderson.org/newsroom/research-newsroom/aacr-clinical-trial-feature-advances-across-cancer-care.h00-159854556.html
[5] AACR Meeting News. "Fourth Clinical Trials Plenary Session Highlighted Emerging Developments in Immunotherapy." AACR Meeting News. https://www.aacrmeetingnews.org/fourth-clinical-trials-plenary-session-highlighted-emerging-developments-in-immunotherapy/
[6] AACR. "Distribution of Phase I Lung Cancer Trials May Be Consolidating at Top-Performing U.S. Sites." AACR Newsroom, News Releases. https://www.aacr.org/about-the-aacr/newsroom/news-releases/distribution-of-phase-i-lung-cancer-trials-may-be-consolidating-at-top-performing-u-s-sites/
[7] AACR Meeting News. "New Drugs on the Horizon Sessions Will Offer First Look at Diverse Therapeutics." AACR Meeting News. https://www.aacrmeetingnews.org/new-drugs-on-the-horizon-sessions-will-offer-first-look-at-diverse-therapeutics/
[8] AACR Meeting News. "Second Set of Meet-the-Expert Sessions Will Span Broad Range of Topics from Renowned Presenters." AACR Meeting News. https://www.aacrmeetingnews.org/second-set-of-meet-the-expert-sessions-will-span-broad-range-of-topics-from-renowned-presenters/
[9] eCANCER. "Positive Data Presented for B7-H4-Targeted ADC in Gynaecological Cancers." eCANCER, April 28, 2024. https://ecancer.org/en/news/28084-positive-data-presented-for-b7-h4-targeted-adc-in-gynaecological-cancers